The decreased frequency of CCR6+ cells in Population III and low numbers of CCR6+ activated/memory Treg in Population II in some MS patients, suggested that failure to produce Th17-like Treg may contribute to lack of control of inflammation in MS. The gene discussed is CCR6; the disease is myeloid sarcoma.